Cometriq (cabozantinib) — CareFirst (Caremark)
Non-small cell lung cancer with RET gene rearrangements
Initial criteria
- Used as a single agent for treatment of recurrent, advanced, or metastatic NSCLC with RET gene rearrangements
- Member has not experienced disease progression on therapy with a RET rearrangement positive-targeted regimen
- Submission of RET gene rearrangement documentation
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months